Epigenetic age clocks and mortality at the individual level — methodological review

clinical paper · 2023

type:clinical paper

year:2023

citation:Representative methodological review of epigenetic age clocks as predictors of individual-level mortality and disease incidence. Exact citation pending verification; the canonical reference for the surrogate-endpoint critique of epigenetic-clock-based aging interventions includes work by Bell, Lu, Levine, Horvath, and others on clock validation against chronological age, all-cause mortality, and disease incidence. The general finding: epigenetic clocks are validated as population-level predictors of chronological age and average mortality risk; they are not validated as causal mediators of individual-level mortality, and movement on the clock surrogate does not, in current evidence, predict downstream hard-endpoint benefit for an individual recipient of an intervention designed to reduce clock-measured biological age.

SUMMARY

Representative reference for the methodological critique of epigenetic-clock-based surrogate endpoints in aging-intervention research. The critique applies broadly to the contemporary longevity-medicine industry, in which most marketing claims rest on movement of an epigenetic clock or related biological-age surrogate rather than on hard clinical outcomes (mortality, disease incidence, functional capacity). The TPE-IVIG case is graded against this critique: the trial reports significant movement on a multi-clock surrogate panel, but movement of the surrogate is not equivalent to clinical rejuvenation, and the gap between surrogate and hard endpoint is the central methodological issue in evaluating the trial's clinical implications.

NOTES

The epigenetic-clock-and-mortality methodological literature is the appropriate reference for evaluating whether movement on the surrogate endpoints used in the TPE-IVIG trial translates to clinical benefit. The literature is not in dispute on the core point: clocks are well-validated against chronological age and against population-level mortality, but the individual-level causal mediation has not been established, and most clinical claims based on clock movement go beyond what the surrogate-endpoint evidence supports. The reference is the principal critical counter to the marketing-facing extrapolation of the trial findings.